Login to Your Account



There’s always ‘Tesaro’: antibody bet brings $17M up front to Anaptysbio

By Randy Osborne
Staff Writer

Thursday, March 13, 2014

Anaptysbio Inc.’s SHM-XEL antibody-making platform that replicates somatic hypermutation in vitro drew yet another partner, this time Tesaro Inc., which agreed to pay $17 million up front for rights to three cancer antibody programs and could fork over as much as $108 million per target.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription